1.Production, characterization, and clinical application of perchloric acid extract of M. bovis BCG (BCG I).
Journal of the Korean Pediatric Society 1992;35(8):1059-1065
No abstract available.
Mycobacterium bovis*
2.The Necessity of a Nationwide Surveillance System of Serious BCG Adverse Reactions.
Journal of Korean Medical Science 2019;34(1):e10-
No abstract available.
Mycobacterium bovis*
3.Differentiation between Mycobacterium bovis and Mycobacterium tuberculosis Infection.
Won Jung KOH ; Young Kil PARK ; Chang Ki KIM
Korean Journal of Medicine 2012;83(4):550-552
No abstract available.
Mycobacterium
;
Mycobacterium bovis
;
Mycobacterium tuberculosis
4.PPD Conversion Rate and Complications According to the Different Time of BCG Vaccination.
Kyung Hyo KIM ; Seung Joo LEE ; Keun LEE
Journal of the Korean Pediatric Society 1987;30(5):487-490
No abstract available.
Mycobacterium bovis*
;
Vaccination*
6.The effectiveness of the antiidiotypic monoclonal antibody therapy conjugated to KLH and BCG in malignant melanoma.
Jeoung Won BAE ; Cheung Wung WHANG ; Sae Min KIM ; S FERRONE
Journal of the Korean Surgical Society 1993;44(3):322-333
No abstract available.
Melanoma*
;
Mycobacterium bovis*
7.Effects of BCG infection on the multiplication of R.tsutsugamushi in the mouse.
Bok Soo LEE ; Yung Kwon HONG ; Chang Duk JUN ; In Jae KIM ; Hun Taek JUNG ; Suk Don PARK ; Ik Sang KIM ; Woo Hyun CHANG
Korean Journal of Infectious Diseases 1993;25(2):91-101
No abstract available.
Animals
;
Mice*
;
Mycobacterium bovis*
8.Pilot production of live, cryoprecipitate BCG (Im.BCG).
Journal of Preventive Medicine 1999;9(1):57-61
The live and cryoprecipitate BCG had been produced successfully at Nha Trang - Da Lat Institute of vaccine and biological substances (Im. BCG) of 37.5 mg/vial met standard of Ha Noi National Center for Vaccine and Biological substance control and WHO. Im.BCG met the standards of the sterillization and the safety. The live unit attained 2.6 +/- 0.54 x 108 per vial, the rate of thermal stability was 58.2 +/- 0.023, the dispension density was 1.22 +/- 0.119 and the additive huminity was 2.46 +/- 0.27%.
Mycobacterium bovis
;
vaccines
9.Pilot production of live, cryoprecipitate BCG (Im.BCG)
Journal of Preventive Medicine 2002;12(6):57-61
The live and cryoprecipitate BCG had been produced successfully at Nha Trang - Da Lat Institute of vaccine and biological substances (Im. BCG) of 37.5 mg/vial met standard of Ha Noi National Center for Vaccine and Biological substance control and WHO. Im.BCG met the standards of the sterillization and the safety. The live unit attained 2.6 +/- 0.54 x 108 per vial, the rate of thermal stability was 58.2 +/- 0.023, the dispension density was 1.22 +/- 0.119 and the additive huminity was 2.46 +/- 0.27%.
Mycobacterium bovis
;
vaccines
10.Pham Ngoc Thach and his researcher on BCG at 43oC.
Journal of Medical and Pharmaceutical Information 2000;(4):3-6
This paper introduced systematically the classic knowledge of the anti-tuberculosis immune, the reasons, objectives and situation of researches on died BCG in the foreign countries. The studies on the rate of infection and immunization for live BCG, BCG at 43oC, fatty lost BCG and standard BCG in experimental mice have shown that the immunal rate by hypodermic and intradermic injection of died BCG due to the long keeping or keeping at 43oC was the same as this by the live BCG injection. In addition to, the died BCG showed further some advantages.
Mycobacterium bovis
;
vaccines
Result Analysis
Print
Save
E-mail